Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Elsa Shapiro; Jessica Bernstein; Heather R. Adams; Ann J. Barbier; Teresa Buracchio; Peter Como; Kathleen A. Delaney; Florian Eichler; Jonathan C. Goldsmith; Melissa Hogan; Sarrit Kovacs; Jonathan W. Mink; Joanne Odenkirchen; Melissa A. Parisi; Alison Skrinar; Susan E. Waisbren; Andrew E. Mulberg

doi:10.1016/j.ymgme.2016.04.006

Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Elsa Shapiro, Jessica Bernstein, Heather R. Adams, Ann J. Barbier, Teresa Buracchio, Peter Como, Kathleen A. Delaney, Florian Eichler, Jonathan C. Goldsmith, Melissa Hogan, Sarrit Kovacs, Jonathan W. Mink, Joanne Odenkirchen, Melissa A. Parisi, Alison Skrinar, Susan E. Waisbren, Andrew E. Mulberg

Research output: Contribution to journal › Comment/debate › peer-review

27 Scopus citations

Abstract

Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

Original language	English (US)
Pages (from-to)	65-69
Number of pages	5
Journal	Molecular Genetics and Metabolism
Volume	118
Issue number	2
DOIs	https://doi.org/10.1016/j.ymgme.2016.04.006
State	Published - Jun 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Published by Elsevier Inc.

Keywords

Clinical outcome assessment
Drug development
Inborn errors
Natural history studies
Neurocognitive
Rare diseases

Publisher link

10.1016/j.ymgme.2016.04.006

http://europepmc.org/articles/pmc4895194

Find It

Find It at U of M Libraries

Cite this

Shapiro, E., Bernstein, J., Adams, H. R., Barbier, A. J., Buracchio, T., Como, P., Delaney, K. A., Eichler, F., Goldsmith, J. C., Hogan, M., Kovacs, S., Mink, J. W., Odenkirchen, J., Parisi, M. A., Skrinar, A., Waisbren, S. E., & Mulberg, A. E. (2016). Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism, 118(2), 65-69. https://doi.org/10.1016/j.ymgme.2016.04.006

Shapiro, E, Bernstein, J, Adams, HR, Barbier, AJ, Buracchio, T, Como, P, Delaney, KA, Eichler, F, Goldsmith, JC, Hogan, M, Kovacs, S, Mink, JW, Odenkirchen, J, Parisi, MA, Skrinar, A, Waisbren, SE & Mulberg, AE 2016, 'Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions', Molecular Genetics and Metabolism, vol. 118, no. 2, pp. 65-69. https://doi.org/10.1016/j.ymgme.2016.04.006

@article{5f31f082a17242c8b21a140d5b662b4b,

title = "Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions",

abstract = "Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, {"}Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism.{"} Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.",

keywords = "Clinical outcome assessment, Drug development, Inborn errors, Natural history studies, Neurocognitive, Rare diseases",

author = "Elsa Shapiro and Jessica Bernstein and Adams, {Heather R.} and Barbier, {Ann J.} and Teresa Buracchio and Peter Como and Delaney, {Kathleen A.} and Florian Eichler and Goldsmith, {Jonathan C.} and Melissa Hogan and Sarrit Kovacs and Mink, {Jonathan W.} and Joanne Odenkirchen and Parisi, {Melissa A.} and Alison Skrinar and Waisbren, {Susan E.} and Mulberg, {Andrew E.}",

note = "Publisher Copyright: {\textcopyright} 2016 Published by Elsevier Inc.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.ymgme.2016.04.006",

language = "English (US)",

volume = "118",

pages = "65--69",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

AU - Shapiro, Elsa

AU - Bernstein, Jessica

AU - Adams, Heather R.

AU - Barbier, Ann J.

AU - Buracchio, Teresa

AU - Como, Peter

AU - Delaney, Kathleen A.

AU - Eichler, Florian

AU - Goldsmith, Jonathan C.

AU - Hogan, Melissa

AU - Kovacs, Sarrit

AU - Mink, Jonathan W.

AU - Odenkirchen, Joanne

AU - Parisi, Melissa A.

AU - Skrinar, Alison

AU - Waisbren, Susan E.

AU - Mulberg, Andrew E.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

AB - Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

KW - Clinical outcome assessment

KW - Drug development

KW - Inborn errors

KW - Natural history studies

KW - Neurocognitive

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=84964573652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964573652&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2016.04.006

DO - 10.1016/j.ymgme.2016.04.006

M3 - Comment/debate

C2 - 27132782

AN - SCOPUS:84964573652

SN - 1096-7192

VL - 118

SP - 65

EP - 69

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 2

ER -

Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this